<p>CervoMed Inc.（纳斯达克代码：CRVO - 免费报告）- Roth Capital 的研究分析师在 8 月 11 日星期一向投资者发布的报告中下调了对 CervoMed 2025 年第三季度每股收益的预期。Roth Capital 分析师 B. Pachaiyappan 现在预测该公司本季度每股收益为（$0.76），低于之前预测的（$0.50）。Roth Capital 目前对该股票的评级为 “买入”，目标价为 16.00 美元。市场普遍预期 CervoMed 当前全年的每股收益为（$1.88）。Roth Capital 还对 CervoMed 2025 年第四季度的每股收益预期为（$0.49），2025 财年的每股收益预期为（$2.51），2026 年第一季度的每股收益预期为（$0.61），2026 年第二季度的每股收益预期为（$0.63），2026 年第三季度的每股收益预期为（$0.71），2026 年第四季度的每股收益预期为（$0.75），以及 2026 财年的每股收益预期为（$2.71）。</p>
<p>CervoMed（纳斯达克代码：CRVO - 获取免费报告）最近于 8 月 8 日星期五发布了季度财报。该公司报告本季度每股收益为（$0.70），低于分析师普遍预期的（$0.57），差额为（$0.13）。CervoMed 的净利润率为负的 290.72%，股本回报率为负的 59.15%。该公司本季度的收入为 176 万美元，而分析师预期为 145 万美元。</p>
<p>其他一些研究公司也最近对 CRVO 发表了评论。Canaccord Genuity Group 将 CervoMed 的目标股价从 21.00 美元上调至 27.00 美元，并在 7 月 29 日的研究报告中给予该股票 “买入” 评级。Chardan Capital 在周一重申了 “买入” 评级，并将 CervoMed 的目标价设定为 15.00 美元。最后，D. Boral Capital 在周一将 CervoMed 的目标股价从 10.00 美元上调至 15.00 美元，并给予该公司 “买入” 评级。一位股票研究分析师对该股票给予了卖出评级，一位给予了持有评级，六位给予了买入评级，还有一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 21.43 美元。</p>
<p><strong>查看我们对 CRVO 的最新分析</strong></p>
<h2>CervoMed 股票表现</h2>
<p>CRVO 周四开盘价为 9.64 美元。CervoMed 的 52 周最低价为 1.80 美元，最高价为 20.63 美元。该公司的 50 日移动平均线为 7.64 美元，200 日移动平均线为 7.05 美元。该股票的市值为 8920 万美元，市盈率为-3.69，贝塔值为-0.79。</p>
<h2>对 CervoMed 的对冲基金看法</h2>
<p>几家大型投资者最近对 CRVO 的持仓进行了调整。Rhumbline Advisers 在第一季度将其在 CervoMed 的股份增加了 35.5%。Rhumbline Advisers 目前拥有 5830 股该公司的股票，价值 53,000 美元，此前在此期间又购买了 1526 股。HighTower Advisors LLC 在第一季度购买了 CervoMed 的新股份，价值约为 104,000 美元。Marshall Wace LLP 在第二季度购买了 CervoMed 的新股份，价值约为 76,000 美元。纽约梅隆银行在第一季度购买了 CervoMed 的新股份，价值为 110,000 美元。最后，Mariner LLC 在第四季度购买了 CervoMed 的新股份，价值为 30,000 美元。目前，25.15% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 CervoMed</h2>
<p>（获取免费报告）</p>
<p>CervoMed Inc. 是一家生物技术公司，专注于开发和商业化针对与年龄相关的神经系统疾病的治疗。其主要药物候选者是 neflamapimod，这是一种口服小分子药物，能够穿透大脑，用于治疗路易体痴呆（DLB）、阿尔茨海默病、额颞叶痴呆和缺血性中风恢复。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 CervoMed</li>
<li>便士股票适合你的投资组合吗？</li>
<li>数据中心为这三只核能股票创造了牛市前景</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>特斯拉的旗形图形刚刚破裂：这对股票意味着什么</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>三家公司将从特朗普的半导体关税中获利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 CervoMed 吗？</h2>
<p>在考虑 CervoMed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CervoMed 并不在名单上。</p>
<p>虽然 CervoMed 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CRVO

<p>Roth Capital 已将 CervoMed Inc. (NASDAQ:CRVO) 2025 年第三季度每股收益（EPS）预估从（$0.50）下调至（$0.76）。该公司维持 “买入” 评级，目标价为 $16.00。CervoMed 最近的财报显示每股亏损（$0.70），未能达到预期。分析师对该股票的评级不一，平均评级为 “适度买入”，共识目标价为 $21.43。CervoMed 专注于治疗与年龄相关的神经系统疾病，其主要候选药物为 neflamapimod</p>

<p>CervoMed Inc. (NASDAQ:CRVO - Free Report) - Research analysts at Roth Capital cut their Q3 2025 EPS estimates for CervoMed in a note issued to investors on Monday, August 11th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their previous forecast of ($0.50). Roth Capital currently has a &#34;Buy&#34; rating and a $16.00 price target on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed's Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($2.51) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.71) EPS.</p>
<div class="lb-trans"><p>CervoMed Inc.（纳斯达克代码：CRVO - 免费报告）- Roth Capital 的研究分析师在 8 月 11 日星期一向投资者发布的报告中下调了对 CervoMed 2025 年第三季度每股收益的预期。Roth Capital 分析师 B. Pachaiyappan 现在预测该公司本季度每股收益为（$0.76），低于之前预测的（$0.50）。Roth Capital 目前对该股票的评级为 “买入”，目标价为 16.00 美元。市场普遍预期 CervoMed 当前全年的每股收益为（$1.88）。Roth Capital 还对 CervoMed 2025 年第四季度的每股收益预期为（$0.49），2025 财年的每股收益预期为（$2.51），2026 年第一季度的每股收益预期为（$0.61），2026 年第二季度的每股收益预期为（$0.63），2026 年第三季度的每股收益预期为（$0.71），2026 年第四季度的每股收益预期为（$0.75），以及 2026 财年的每股收益预期为（$2.71）。</p>
</div><p>CervoMed (NASDAQ:CRVO - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. The firm had revenue of $1.76 million during the quarter, compared to analysts' expectations of $1.45 million.</p>
<div class="lb-trans"><p>CervoMed（纳斯达克代码：CRVO - 获取免费报告）最近于 8 月 8 日星期五发布了季度财报。该公司报告本季度每股收益为（$0.70），低于分析师普遍预期的（$0.57），差额为（$0.13）。CervoMed 的净利润率为负的 290.72%，股本回报率为负的 59.15%。该公司本季度的收入为 176 万美元，而分析师预期为 145 万美元。</p>
</div><p>A number of other research firms have also recently commented on CRVO. Canaccord Genuity Group boosted their target price on shares of CervoMed from $21.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, July 29th. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $15.00 price objective on shares of CervoMed in a research note on Monday. Finally, D. Boral Capital boosted their target price on shares of CervoMed from $10.00 to $15.00 and gave the company a &#34;buy&#34; rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $21.43.</p>
<div class="lb-trans"><p>其他一些研究公司也最近对 CRVO 发表了评论。Canaccord Genuity Group 将 CervoMed 的目标股价从 21.00 美元上调至 27.00 美元，并在 7 月 29 日的研究报告中给予该股票 “买入” 评级。Chardan Capital 在周一重申了 “买入” 评级，并将 CervoMed 的目标价设定为 15.00 美元。最后，D. Boral Capital 在周一将 CervoMed 的目标股价从 10.00 美元上调至 15.00 美元，并给予该公司 “买入” 评级。一位股票研究分析师对该股票给予了卖出评级，一位给予了持有评级，六位给予了买入评级，还有一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 21.43 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on CRVO</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CRVO 的最新分析</strong></p>
</div><h2>CervoMed Stock Performance</h2>
<div class="lb-trans"><h2>CervoMed 股票表现</h2>
</div><p>CRVO opened at $9.64 on Thursday. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $20.63. The company has a fifty day moving average of $7.64 and a two-hundred day moving average of $7.05. The stock has a market capitalization of $89.20 million, a price-to-earnings ratio of -3.69 and a beta of -0.79.</p>
<div class="lb-trans"><p>CRVO 周四开盘价为 9.64 美元。CervoMed 的 52 周最低价为 1.80 美元，最高价为 20.63 美元。该公司的 50 日移动平均线为 7.64 美元，200 日移动平均线为 7.05 美元。该股票的市值为 8920 万美元，市盈率为-3.69，贝塔值为-0.79。</p>
</div><h2>Hedge Funds Weigh In On CervoMed</h2>
<div class="lb-trans"><h2>对 CervoMed 的对冲基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in CRVO. Rhumbline Advisers increased its stake in CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after buying an additional 1,526 shares during the period. HighTower Advisors LLC purchased a new stake in shares of CervoMed in the 1st quarter valued at approximately $104,000. Marshall Wace LLP purchased a new stake in shares of CervoMed in the 2nd quarter valued at approximately $76,000. Bank of New York Mellon Corp purchased a new position in shares of CervoMed in the 1st quarter valued at $110,000. Finally, Mariner LLC purchased a new position in shares of CervoMed in the 4th quarter valued at $30,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家大型投资者最近对 CRVO 的持仓进行了调整。Rhumbline Advisers 在第一季度将其在 CervoMed 的股份增加了 35.5%。Rhumbline Advisers 目前拥有 5830 股该公司的股票，价值 53,000 美元，此前在此期间又购买了 1526 股。HighTower Advisors LLC 在第一季度购买了 CervoMed 的新股份，价值约为 104,000 美元。Marshall Wace LLP 在第二季度购买了 CervoMed 的新股份，价值约为 76,000 美元。纽约梅隆银行在第一季度购买了 CervoMed 的新股份，价值为 110,000 美元。最后，Mariner LLC 在第四季度购买了 CervoMed 的新股份，价值为 30,000 美元。目前，25.15% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About CervoMed</h2>
<div class="lb-trans"><h2>关于 CervoMed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.</p>
<div class="lb-trans"><p>CervoMed Inc. 是一家生物技术公司，专注于开发和商业化针对与年龄相关的神经系统疾病的治疗。其主要药物候选者是 neflamapimod，这是一种口服小分子药物，能够穿透大脑，用于治疗路易体痴呆（DLB）、阿尔茨海默病、额颞叶痴呆和缺血性中风恢复。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than CervoMed</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Data Centers Create a Bull Case for These Nuclear 3 Stocks</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>3 Companies That Will Profit From Trump's Semiconductor Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 CervoMed</li>
<li>便士股票适合你的投资组合吗？</li>
<li>数据中心为这三只核能股票创造了牛市前景</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>特斯拉的旗形图形刚刚破裂：这对股票意味着什么</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>三家公司将从特朗普的半导体关税中获利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CervoMed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 CervoMed 吗？</h2>
</div><p>Before you consider CervoMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CervoMed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CervoMed 并不在名单上。</p>
</div><p>While CervoMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CervoMed 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

罗斯资本对 CervoMed 第三季度收益的预测持悲观态度